Skip to content
Centre de référence des microangiopathies thrombotiques
Accessibilité
800x600 Résolution intermédiaire Plein écran Augmenter la taille des caractères Réduire la taille des caractères Taille des caractères par défaut
Bannière
Bannière

Articles médicaux - 2023

PDFImprimerEmail
Écrit par Paul Coppo
ARTICLES EN ANGLAIS
How I treat thrombotic microangiopathy in the era of rapid genomics. Doreille A, et al. Blood. 2023 Jan 12;141(2):147-155.

Preemptive cyclosporin A in immune-mediated thrombotic thrombocytopenic purpura. Comparon C, Galicier L, Rebibou JM, Coppo P, Benhamou Y. Eur J Haematol. 2023 Feb;110(2):157-160. doi: 10.1111/ejh.13886. Epub 2022 Nov 14.

ADAMTS13 conformation is closed in non-immune acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology. Joly BS, Roose E, Coppo P, Vanhoorelbeke K, Veyradier A. Haematologica. 2023 Feb 1;108(2):638-644. doi: 10.3324/haematol.2022.280768.

Reversible skin microvascular hyporeactivity in patients with immune-mediated thrombocytopenic thrombotic purpura. Joffre J, Raia L, Urbina T, Bonny V, Gabarre P, Missri L, Baudel JL, Coppo P, Guidet B, Maury E, Ait-Oufella H. Crit Care. 2023 Mar 21;27(1):116. doi: 10.1186/s13054-023-04405-w.

The Specificities of Thrombotic Thrombocytopenic Purpura at Extreme Ages: A Narrative Review. Joseph A, Joly BS, Picod A, Veyradier A, Coppo P. J Clin Med. 2023 Apr 23;12(9):3068. doi: 10.3390/jcm12093068.

Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severity. Tellier E, Widemann A, Cauchois R, Faccini J, Lagarde M, Brun M, Robert P, Robert S, Bachelier R, Poullin P, Roose E, Vanhoorelbeke K, Coppo P, Dignat-George F, Kaplanski G. Haematologica. 2023 Apr 1;108(4):1127-1140. doi: 10.3324/haematol.2022.280651.

Differences in IgG autoantibody Fab glycosylation across autoimmune diseases. Koers J, Sciarrillo R, Derksen NIL, Vletter EM, Fillié-Grijpma YE, Raveling-Eelsing E, Graça NAG, Leijser T, Pas HH, Laura van Nijen-Vos L, Braham MVJ, Buisman AM, de Jong J, Schriek AI, Tio-Gillen AP, Teng YKO, Steenhuis M, Swaneveld FH, de Taeye SW, van Gils MJ, Verschuuren JJGM, Rutgers B, Heeringa P, Horváth B, Jacobs BC, de Leeuw K, Franssen CFM, Veyradier A, Coppo P, Gelderman KA, Marieke van Ham S, van Els CACM, van der Woude D, Huizinga R, Huijbers MG, Kuijpers TW, Toes REM, Bos NA, Rispens T; T2B Consortium. J Allergy Clin Immunol. 2023 Jun;151(6):1646-1654. doi: 10.1016/j.jaci.2022.10.035. Epub 2023 Jan 27.

More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura. Picod A, Benhamou Y, Bouzid R, Veyradier A, Coppo P. Blood Adv. 2023 Jun 27;7(12):2678-2680. doi: 10.1182/bloodadvances.2022009021.

Predictors of acute ischemic cerebral lesions in immune-mediated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Neuman L, Joseph A, Bouzid R, Lescroart M, Mariotte E, Ederhy S, Tuffet S, Baudel JL, Benhamou Y, Galicier L, Grangé S, Provôt F, Neel A, Pène F, Delmas Y, Presne C, Poullin P, Wynckel A, Perez P, Barbet C, Halimi JM, Chatelet V, Rebibou JM, Ojeda-Uribe M, Vigneau C, Mesnard L, Veyradier A, Azoulay E, Coppo P, Chabriat H; participants to the Prospective Multicenter MATRISK study. J Neurol. 2023 Oct;270(10):5023-5033. doi: 10.1007/s00415-023-11830-y. Epub 2023 Jul 1.
 
Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura? Coppo P, Joly BS; French Reference Center for Thrombotic Microangiopathies (CNR-MAT). Br J Haematol. 2023 Aug;202(4):725-727. doi: 10.1111/bjh.18915. Epub 2023 Jun 8.

Measuring ADAMTS-13 activity to diagnose thrombotic thrombocytopenic purpura: a novel, fast fiber-optic surface plasmon resonance immunoassay. Bonnez Q, Dekimpe C, Tellier E, Kaplanski G, Verhamme P, Tersteeg C, De Meyer SF, Lammertyn J, Joly B, Coppo P, Veyradier A, Vanhoorelbeke K. Res Pract Thromb Haemost. 2023 Aug 19;7(6):102171. doi: 10.1016/j.rpth.2023.102171. eCollection 2023 Aug.

Post-traumatic stress disorder and quality of life alterations in survivors of immune-mediated thrombotic thrombocytopenic purpura and atypical hemolytic and uremic syndrome. Azoulay E, Souppart V, Kentish-Barnes N, Benhamou Y, Joly BS, Zafrani L, Joseph A, Canet E, Presne C, Grall M, Zerbib Y, Provot F, Fadlallah J, Mariotte E, Urbina T, Veyradier A, Coppo P. J Crit Care. 2023 Aug;76:154283. doi: 10.1016/j.jcrc.2023.154283. Epub 2023 Mar 15.

High sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio in Pregnancy-Onset Thrombotic Thrombocytopenic Purpura. Béranger N, Tsatsaris V, Coppo P, Veyradier A, Joly BS. Hypertension. 2023 Sep;80(9):e140-e142. doi: 10.1161/HYPERTENSIONAHA.123.20987. Epub 2023 May 12.

Efficacy and Safety of Rituximab-Based Treatments in Angioedema With Acquired C1-Inhibitor Deficiency. Kalmi G, Nguyen Y, Amarger S, Aubineau M, Bibes B, Blanchard-Delaunay C, Boccon-Gibod I, Bouillet L, Coppo P, Dalmas MC, Debord-Peguet S, Defendi F, Demoreuil C, Du-Thanh A, Gayet S, Hadjadj J, Jeandel PY, Launay D, Ly KH, Avoy CM, Niault M, Ollivier Y, Pelletier F, Porneuf M, Roos-Weil D, Fain O, Gobert D. J Allergy Clin Immunol Pract. 2023 Oct 14:S2213-2198(23)01134-0. doi: 10.1016/j.jaip.2023.10.017.

The challenging follow-up of pregnancy in women with known thrombotic thrombocytopenic purpura: a single-center experience of a preemptive management protocol. Hamroun A, Prouteau C, Lenain R, Roger C, Bauters A, Zawadzki C, Subtil D, Gibier JB, Stichelbout M, Coppo P, Lionet A, Maanaoui M, Hazzan M, Provôt F. J Nephrol. 2023 Dec;36(9):2519-2529. doi: 10.1007/s40620-023-01790-x. Epub 2023 Oct 11.

Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura. De Waele L, Sakai K, Mancini I, Sinkovits G, Falter T, Inoue T, Agosti P, Rossmann H, Von Auer C, Tersteeg C, De Meyer SF, Joly BS, Veyradier A, Coppo P, Fijnheer R, Peyvandi F, Prohászka Z, Lämmle B, Vanhoorelbeke K. J Thromb Haemost. 2023 Oct 20:S1538-7836(23)00783-3. doi: 10.1016/j.jtha.2023.10.014.

The Metamorphosis, struggling to adapt to a new condition. The lived experience of patients with Thrombotic microangiopathies diagnosed in the ICU. A qualitative study. Kentish-Barnes N, Souppart V, Cohen-Solal Z, Benhamou Y, Coppo P, Veyradier A, Azoulay E. J Crit Care. 2023 Dec;78:154366. doi: 10.1016/j.jcrc.2023.154366. Epub 2023 Jul 13.

Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura. Postmus T, Graça NAG, Ferreira de Santana J, Ercig B, Langerhorst P, Luken B, Joly BS, Vanhoorelbeke K, Veyradier A, Coppo P, Voorberg J. J Thromb Haemost. 2023 Dec;21(12):3402-3413. doi: 10.1016/j.jtha.2023.08.017. Epub 2023 Aug 25.

Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience. Béranger N, Coppo P, Tsatsaris V, Boisseau P, Provôt F, Delmas Y, Poullin P, Vanhoorelbeke K, Veyradier A, Joly BS. Blood Adv. 2024 Jan 9;8(1):183-193. doi: 10.1182/bloodadvances.2023011972.

Mis à jour le 03 Janvier 2024

Le CNR-MAT souhaite vous offrir la meilleure expérience possible sur son site. En poursuivant votre navigation, vous acceptez l’utilisation des cookies permettant d'étudier l’audience du site et de vous proposer du contenu et des services adaptés à votre intérêt pour les MAT. Pour en savoir plus, consultez notre politique cookies

J'accepte les cookies sur ce site